Exozymes Inc. SEC filings EXOZ

Exozymes Inc. has 128 filings in SEC EDGAR's recent list, going back to Feb 9, 2024. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 9, 2026 (other events). The company's fiscal year ends on December 31.

Exozymes Inc. SEC filings
Form Description Filed Period
EFFECT Filing Jan 23, 2026 —
CORRESP Letter to the SEC Jan 22, 2026 —
DRS Filing Dec 15, 2025 —
DEFR14A Filing Jun 23, 2025 —
D Filing Nov 19, 2024 —
CERT Filing Nov 12, 2024 —
EFFECT Filing Nov 8, 2024 —
CORRESP Letter to the SEC Nov 6, 2024 —
CORRESP Letter to the SEC Nov 6, 2024 —
CORRESP Letter to the SEC Oct 31, 2024 —
UPLOAD Letter from the SEC Oct 30, 2024 —
CORRESP Letter to the SEC Oct 25, 2024 —
CORRESP Letter to the SEC Oct 9, 2024 —
CORRESP Letter to the SEC Oct 7, 2024 —
CORRESP Letter to the SEC Oct 7, 2024 —
CORRESP Letter to the SEC Sep 26, 2024 —
UPLOAD Letter from the SEC Sep 23, 2024 —
CORRESP Letter to the SEC Sep 19, 2024 —
UPLOAD Letter from the SEC Sep 17, 2024 —
CORRESP Letter to the SEC Sep 6, 2024 —
UPLOAD Letter from the SEC Aug 8, 2024 —
8-A12B Filing Aug 1, 2024 —
CORRESP Letter to the SEC May 22, 2024 —
UPLOAD Letter from the SEC Apr 30, 2024 —
CORRESP Letter to the SEC Apr 17, 2024 —
UPLOAD Letter from the SEC Mar 13, 2024 —

Showing 26 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
EXOZ (Nasdaq)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
Monrovia, CA
SEC filer status
, Emerging growth company
SEC CIK
2010788
Former names
Invizyne Technologies Inc (until Jan 21, 2025)

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.